Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma

Haematologica

Volumn 85, Issue 6, 2000, Pages 613-618

  Jerusalem, Guy ^a,b   Beguin, Yves ^a   Fassotte, Marie France ^a   Najjar, Fadi ^a   Paulus, Patrick ^a   Rigo, Pierre ^a   Fillet, Georges ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b CHU SART TILMAN   (Belgium)

Author keywords

Fluorine 18 fluorodeoxyglucose; Non Hodgkin's lymphoma; PET imaging; Treatment outcome

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; FLUORODEOXYGLUCOSE F 18; MITOXANTRONE; DIAGNOSTIC AGENT; FLUORINE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SCINTISCANNING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG INDUCED DISEASE; DRUG UPTAKE; FEMALE; HUMAN; MALE; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PREDICTION; TREATMENT FAILURE; TREATMENT OUTCOME; COMPUTER ASSISTED EMISSION TOMOGRAPHY; METABOLISM; MIDDLE AGED; PREDICTION AND FORECASTING; PROGNOSIS; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOPHARMACEUTICALS; SURVIVAL RATE; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 0033624050     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Armitage JO, Weisenburger DD, Hutchins M, et al. Chemotherapy for diffuse large-cell lymphoma - rapidly responding patients have more durable remissions. J Clin Oncol 1986; 4:160-4.
2. Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol 1988; 6:931-3.
3. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94:429-33.
4. Warburg O. On the origin of cancer cell. Science 1956; 123:309-14.
5. Callagher BM, Fowler JS, Gutterson NI, Mac Gregor RR, Wan CN, Wolf AP. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of (F-18)-2-deoxy-2-fluoro-D-glucose. J Nucl Med 1978; 19:1154-61.
6. Römer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998; 91:4464-71.
7. Rahmouni A, Tempany C, Jones R, Mann R, Yang A, Zerhouni E. Lymphoma: monitoring tumor size and signal intensity with MRI imaging. Radiology 1993; 188:445-51.
8. Kaplan WD, Jochelson MS, Herman TS, et al. Gallium-67 imaging: a predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma. J Clin Oncol 1990; 8:1966-70.
9. Janicek M, Kaplan W, Neuberg, Canellos GP, Shulman LN, Shipp MA. Early restating gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy. J Clin Oncol 1997; 15:1631-7.
10. Fayad L, Podoloff D, Rodriguez J, et al. Gallium (67Ga) scan result after second course of chemotherapy correlates with clinical outcome in aggressive poor prognosis non-Hodgkin's lymphomas (APPNHL) treated with alternating triple therapy regiment (ATT) [abstract]. Blood 1997; 90(Suppl):189a.
11. Ben Haim S, Bar-Shalom R, Frenkel A, Haim N, Israel O, Front D. Prediction of response in lymphoma patients by Ga-67 scintigraphy after one course of chemotherapy [abstract]. J Nucl Med 1996; 37(Sup-pl):139-40.
12. Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994; 190:111-6.
13. Moog F, Bangerter M, Diederichs CG, et al. Lymphoma: role of whole-body. 2-deoxy-2-[F-18] fluoro-D-glucose (FDG) PET In nodal staging. Radiology 1997; 203:795-800.
14. Moog F, Bangerter M, Diederichs CG, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998; 206:475-81.
15. Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998; 91:3340-6.
16. Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN. 18-F-fluorodeoxyglucose - positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998; 16:603-9.
17. Hoekstra OS, Ossenkoppele GJ, Golding R, et al. Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med 1993; 34:1706-10.
18. Dimitrakopoulou-Strauss A, Strauss LS, Goldschmidt H, Lorenz WJ, Maier-Borst W, Van Kaick G. Evaluation of tumor metabolism and multidrug resistance in patients with treated malignant lymphomas. Eur J Nucl Med 1995; 22:434-42.
19. Zinzani PL, Magagnoli M, Chierichetti F, et al.The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol 1999; 10:1181-4.
20. Jerusalem G, Warland V, Najjar F, et al. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun 1999; 20:13-20.
21. Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med 1995; 36:1836-9.